PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILDALZHEIMER'S DISEASE [SUBSTUDY OF 700240965]
Phase of Trial: Phase III
Latest Information Update: 24 Jun 2016
Price : $35 *
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Roche
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 According to United Kingdom Clinical Research Network record, status changed from recruiting to active, no longer recruiting.
- 30 Apr 2014 New trial record